Additional real-world data demonstrate meaningful outcomes for people living with diabetes who use Abbott's glucose sensing technology
The RECOVERY trial has shown that the cheap and widely available steroid cut deaths by one-third among patients critically ill with COVID-19
It's comprehensive SARS-COV-2 offerings span RT-PCR, high throughput RNA extraction, automation, ELISA and lateral flow based serology testing.
Clinical researchers are this week set to begin human trials of a new coronavirus vaccine developed by researchers at Imperial College London
New diagnostic test for MSI in solid tumors can inform physicians on immuno-oncology therapies and can guide treatment decisions for patients with Lynch-associated cancers
Company exploring further additional global capacity to provide broad and equitable access
llumina's COVIDSeq aims to generate information about the genomic sequence of the virus
Large-scale manufacturing of rapid diagnostic test kit and reagents to enable increased testing capacity for COVID-19 worldwide
The RECOVERY trial has shown that hydroxychloroquine is not an effective treatment in patients hospitalized with COVID-19
Total antibody test aims to deliver superior clinical performance with 100% sensitivity and 99.8% specificity
The trial will study the use of ruxolitinib, a JAK inhibitor, to investigate its effect on reducing complications in deteriorating COVID-19 patients
A rare lung disease drug is being trialed to help fight COVID-19
The study is expected to begin enrolling in June with a target of approximately 450 patients globally
Company to make the device available through broad range of healthcare, state, employer and consumer-initiated channels
The RNAdvance Viral XP is a RNA extraction kit validated for use in infectious disease and real-time PCR virus research
The first 4,000 doses have been delivered for use in the Phase 2/3 clinical trial COV002 by the University of Oxford
First patients are expected to be enrolled shortly and additional European regulatory approvals are in process
People who recovered from COVID-19 shows that most individuals had generated antibodies that were intrinsically capable of neutralizing the SARS-CoV-2 virus
Cambridge Cognition has secured over $1.5 million in new contracts to support pharmaceutical clients in delivering virtual clinical trials
Interim clinical study data shows ID NOW test performance of 94.7% sensitivity and 98.6% specificity
Driven by the gap in COVID-19 testing, the collaboration aims to create a fully disposable, rapid and handheld test for consumers
Study suggests that type I IFN deficiency in the blood could help define a high-risk population
